AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03688438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Incision Negative-Pressure Therapy
Description: A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
Study NCT04352387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montessori Method for Dementia
Description: The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
Study NCT04352387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
Study NCT01633411 — intervention group
Intervention type: DEVICE
Intervention: Focal Cryoballoon Ablation System - 6 seconds
Description: Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications.
Study NCT01633411 — intervention group
Intervention type: DEVICE
Intervention: Focal Cryoballoon Ablation System - 8 seconds
Description: Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications.
Study NCT01633411 — intervention group
Intervention type: DEVICE
Intervention: CryoBalloon Focal Ablation System - 10 seconds
Description: Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications.
Study NCT05808192 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive
Description: compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
Study NCT02382991 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NMPK-3C60
Description: 1 month with NMPK - 3 months with 3C60
Study NCT02645032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT
Description: Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
Study NCT02645032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhim Vi®
Description: Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
Study NCT02645032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAXIGRIP®
Description: Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort.
Study NCT00889850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
Description: 40 mg esomeprazole, single dose administration under fasted and fed condition
Study NCT04183387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Study NCT01374672 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00889850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INexium 40 mg MUPS tablets (AstraZeneca, France)
Description: 40 mg esomeprazole, oral single dose administration under fasted and fed condition
Study NCT03719963 — intervention group
Intervention type: DEVICE
Intervention: Cochlear implant
Description: Cochlear implant for hearing process by surgical intervention
Study NCT03955328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: A magnetic resonance imaging is perform to detect permanent anatomical damage.
Study NCT04657185 — intervention group
Intervention type: OTHER
Intervention: OR PathTrac Feedback Optimization
Description: OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
Study NCT03336086 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: weight loss program
Description: A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
Study NCT02814838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT04294173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video education
Description: tracheostomy care will be given to student nurses with video training
Study NCT02320968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedclineTM Sleep Assist Pillow
Description: The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
Study NCT01708707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days.
Study NCT01708707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
Study NCT02299648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Molecular profiling
Description: molecular profiling, patient derived cells, fresh or FFPE
Study NCT01676441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cellgram-spine
Description: Mesenchymal stem cells transplantation
Study NCT00424346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT00424346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03182413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03182413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Study NCT03182413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102
Study NCT04575831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, Nutrition, and Palliative Symptom Management
Description: 1. Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~2. Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~3. Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake.
Study NCT00868335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activ C disc prosthesis
Description: cervical disc prosthesis
Study NCT00868335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy
Description: Removal of protruding cervical disc through an anterior approach
Study NCT00868335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy
Description: Removal of protruding cervical disc through an anterior approach
Study NCT00795171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel * Sunitinib
Description: docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
Study NCT02636192 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: This is an observational study and participants did not receive any intervention in this study.
Study NCT00795171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel 75mg/m2 day1 q 21d x 4 cycles
Study NCT00795171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 q21d for 4 cycles
Study NCT01874119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Study NCT01874119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fosaprepitant
Description: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Study NCT03457740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula 1
Description: Dietary supplement for strength, testosterone, sexual function, quality of life
Study NCT03457740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula 2
Description: Dietary supplement for strength, testosterone, sexual function, quality of life
Study NCT03457740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparison
Study NCT00944216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salkera Emollient Foam
Description: application of the Salkera emollient foam twice a day during the 12 week study period.
Study NCT04229108 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medopad
Description: Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
Study NCT04260438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Description: single oral administration under fed condition
Study NCT02671955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61610588
Description: Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
Study NCT01039818 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radioiodine
Description: A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
Study NCT01039818 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioiodine
Description: A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
Study NCT04260438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Description: single oral administration under fed condition
Study NCT04260438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Description: single oral administration under fed condition
Study NCT02821052 — intervention group
Intervention type: DRUG
Intervention: insulin degludec/insulin aspart
Description: Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
Study NCT01682616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
Study NCT01682616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
Study NCT03783273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Single dose vitamin D3
Study NCT03783273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Single dose vitamin D3
Study NCT03783273 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Whey protein-complex
Description: Whey protein complex-bound vitamin D3
Study NCT03783273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 500 mL water
Study NCT03783273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 500 mL water
Study NCT03783273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk
Description: 500 mL milk
Study NCT03783273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Juice
Description: 500 mL juice
Study NCT03783273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juice
Description: 500 mL juice
Study NCT02766374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA).
Study NCT02766374 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate.
Study NCT00687089 — intervention group
Intervention type: OTHER
Intervention: Sexual, cognitive functional tests and measurement weight
Study NCT01760525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGM097
Description: Patients treated with CGM097
Study NCT02874209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium MRI
Study NCT02874209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium MRI
Study NCT04015323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current
Description: An electrotherapy current with different carrier frequencies
Study NCT01709838 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: deferasirox
Description: Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT02296021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT02871271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AS-121
Study NCT03378050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART
Description: The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training.
Study NCT03378050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period.
Study NCT04392583 — intervention group
Intervention type: DEVICE
Intervention: ENTACT Septal Staple system
Description: The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
Study NCT01164345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
Study NCT03720379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector S
Description: . All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
Study NCT03720379 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
Study NCT02212288 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples are for metabolic and genetic and biological investigation